The article by Gina Kolata talks about a newly discovered study of 150,000 people carried a rare mutation that was found to be recognized in helping to protect obese people from getting Type 2 Diabetes. The mutation includes also reducing risks of the disease by two-thirds, and is currently being developed into a potential medication treatment to mimic the effect of the mutation. The mutation discovery has been so beneficial and highly anticipated because it is the first mutation where destroying a gene is actually producing an efficient result in humans. The destruction of the copy of the gene is gene ZnT8, although there are known positive effects in humans from this mutation, the mutation in some strains of the mice have shown an opposite effect which destroys the gene and causes the mice to then have diabetes. The mutation functions by destroying a gene ZnT8 that is used by the pancreas cells where the insulin is produced. The rare mutation appears to make slightly more insulin and have a lower blood glucose levels for the entire life. Pfizer, a large pharmaceutical company has already placed great attention to this new discovery and have been working with scientist to fund and aid in the development of creating a treatment drug mimicking the mutation's function. Currently there has been no found negative health effects from the mutations, and that the gene mutation has only proven to destroy the risk of Type 2 Diabetes concluded from the various research populations they drew data from after their testing.
Related Article: https://www.landesbioscience.com/journals/islets/article/9433/
this is a great advancement in medicine. But my only concern is since it is rather new and the first gene to ever do this, is that later down the road is there going to be any negative effects in humans? I wonder if there are any future effects that will come from this. This is a very interesting finding and now I am anxious to see how this plays out in the future.
ReplyDeleteThis is a great article! Maybe one day pharmaceutical companies will be able to take the and "apply" it to type 2 diabetics who do not have the mutation. This could also help give more insight about type 1 diabetes. This article gives a lot of hope!
ReplyDelete